CONNECT WITH US
HealthTech

HealthTech

PhaSER Biomedical Secures $2.7M Gates Foundation Grant to Scale 8HUM Preclinical Models and HERALD AI

HIT Consultant logo

Published on

Add as a preferred source on Google
PhaSER Biomedical Secures $2.7M Gates Foundation Grant to Scale 8HUM Preclinical Models and HERALD AI

Dundee, Scotland-based preclinical and computational drug discovery firm PhaSER Biomedical announced that it has received a $2.7M (£2 million), two-year grant renewal from the Gates Foundation .

The funding extends PhaSER’s participation in the Global Health Discovery Collaboratory, providing worldwide Gates Foundation grantees with unilateral access to PhaSER’s humanised preclinical models and expertise in drug metabolism, pharmacokinetics (DMPK), bioanalysis, and translational study design.

The renewal builds directly on a $2.3 million Gates Foundation award granted in 2024, during which Collaboratory investigators applied PhaSER’s proprietary 8HUM humanised mouse model across global health programs targeting tuberculosis, malaria, schistosomiasis, and Chagas disease.

The 8HUM Platform: Replacing Murine Blind Spots with Human Metabolic Ground Truth

Founded in October 2022 to commercialize transgenic technology developed through a collaboration between Professor Roland Wolf at the University of Dundee, CXR Biosciences, Taconic Farms, and Scottish Enterprise, PhaSER Biomedical re-engineers preclinical candidate validation:

Humanised Hepatic Clearance and Elimination: The 8HUM transgenic mouse model is genetically engineered to express human metabolic pathways governing drug breakdown and elimination. By replicating human pharmacokinetics in vivo, drug developers can establish how a novel compound will behave in humans prior to clinical dosing, preventing late-stage clinical attrition and rescuing viable molecules that fail conventional rodent screens.

Proven Global Health Portfolio Impact: During the initial 2024–2026 Gates Foundation grant cycle, Collaboratory investigators deployed the 8HUM model across high-burden infectious disease pipelines, including tuberculosis, malaria, schistosomiasis, and Chagas disease. The human-relevant data strengthened candidate selection confidence and enabled stalled therapeutic programs to advance toward clinical testing.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.